Apogee Therapeutics Inc. has filed for an initial public offering, according to a filing late Thursday. The biotech company did not provide the number of shares it intends to sell or a price range. Underwriters include Jefferies and TD Cowen, and the company said it would trade on the Nasdaq under the symbol APGE. The company, based in Waltham, Mass., seeks to develop “differentiated” treatments for atopic dermatitis, chronic obstructive pulmonary disease, and other illnesses with “high unmet need.” The company lost $12.5 million, or $2.51 a share, in the three months ended March 31, compared with losses of $4.3 million, or $4.19 a share, in the year-ago period. “Even if this offering is successful, we will require substantial additional capital to finance our operations in the future,” the company wrote as one of its risk factors in the prospectus.
